The Dawn of Federal Oversight
On Friday, January 23, 2026, the landscape of the American hemp industry shifted fundamentally. U.S. Congressman Morgan Griffith (R-VA), Chairman of the House Committee on Energy and Commerce’s Subcommittee on Health, alongside Congressman Marc Veasey (D-TX), officially introduced the Hemp Enforcement, Modernization, and Protection (HEMP) Act of 2026.
This legislation represents a "First-of-its-Kind" regulatory framework intended to end nearly eight years of federal silence following the 2018 Farm Bill. For the thousands of manufacturers and farmers currently navigating a "patchwork" of conflicting state laws, the HEMP Act is being hailed as the beginning of the "Great Professionalization." At Low Gravity Hemp, we view this not just as a compliance hurdle, but as the stabilizing force required to unlock institutional investment and national retail expansion.
A Unified Federal Framework
Since 2018, the FDA has largely declined to regulate hemp-derived CBD and minor cannabinoids as dietary supplements or food additives. This vacuum forced states like Oregon, Tennessee, and Florida to create their own registries and potency caps, making national distribution an operational nightmare.
The HEMP Act seeks to establish a primary federal authority within the FDA. Key provisions include:
- Mandatory FDA Rulemaking: The Health Secretary (currently Robert F. Kennedy Jr.) is directed to initiate a formal rulemaking process to set milligram limits for hemp-derived products.
- The Three-Year Backstop: In a move to prevent further agency foot-dragging, the bill includes an "automatic backstop." If the FDA fails to release a final rule within three years, federal law will automatically establish limits of 5mg per serving and 30mg per package for ingestible cannabinoids.
- Clear Definitions: The bill explicitly excludes "cannabis" (marijuana), ensuring that hemp remains a distinct, federally legal agricultural commodity.
The "Kennedy Factor" and Medicare Promises
The timing of the HEMP Act is no coincidence. Last month, President Donald Trump made a historic promise to explore Medicare and Medicaid coverage for CBD treatments. However, industry lobbyists have noted that without a formal FDA pathway, health insurance providers are legally unable to fulfill that promise.
By empowering the Health Secretary to set "total cannabinoid content" limits within 60 days of passage, the Griffith-Veasey proposal provides the necessary legal bridge to turn "CBD Medicare" into a reality.
Low Gravity Hemp’s Perspective
"While this first step is very important, there is much work yet to be done," says Jonathan Miller, General Counsel of the U.S. Hemp Roundtable. At Low Gravity Hemp, we agree. The HEMP Act is a starting point, but it requires "substantive improvements" to ensure that full-spectrum products and minor cannabinoids—the lifeblood of the wellness industry—aren't inadvertently swept into adult-use-only categories.
The goal of the HEMP Act is clarity. For brands like Low Gravity Hemp, clarity means predictable growth. We are currently analyzing the full text of the bill to ensure our partners are prepared for the transition from "State-to-State" compliance to a "National Federal" standard.
👉 Visit our 2026 Strategy Hub for continued updates on the HEMP Act.
